Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

This study is testing whether a small device implanted in the wall between the two upper chambers of the heart (an interatrial shunt) can reduce the dangerous strain on the right side of the heart in patients with severe pulmonary arterial hypertension — a condition where blood pressure in the lungs is dangerously high. **You may be eligible if...** - You have been diagnosed with Group 1 pulmonary arterial hypertension (PAH), which includes idiopathic (unknown cause), connective tissue disease–related, HIV-related, or congenital heart disease–related PAH - Your symptoms are severe (WHO Functional Class III or IV) despite being on maximum available medication for at least 3 months - You meet specific risk criteria from the 2015 European heart guidelines **You may NOT be eligible if...** - Your oxygen levels drop below 90% at rest without supplemental oxygen - The pressure in the right side of your heart is very high (mean right atrial pressure above 20 mmHg) - You have severe lung disease - You have significant failure of organs other than the right side of your heart - Your left heart function is significantly reduced (ejection fraction below 40%) - The anatomy of your heart does not allow the device to be safely implanted - Your blood vessels cannot accommodate the catheter needed to implant the device Talk to your doctor to see if this trial is right for you.